SUBSCRIBE

BOD Australia Ltd  ASX:BDA

Company

First Coverage

Current Price

Current Return

Highest Return

BOD Australia Ltd ASX:BDA

$ 0.375

-23%

12%

View Company Page
Report Date Price Current Return
FYI and BDA in the news $0.360 4%
BDA is a Medicinal Cannabis Stock with Growing Global Revenues 17-Mar-21 $0.485 -23%
Overlooked ASX Cannabis Stock with a Global Revenue Footprint 17-Mar-21 $0.485 -23%
More US Sales Expected. BDA Fully Funded for Manufacturing Requirements 08-Apr-21 $0.495 -24%
How Our Investments Performed in Q1 of 2021 21-Apr-21 $0.490 -23%
BDA Records Highest Ever Monthly Sales of Medical Cannabis Products 10-May-21 $0.420 -11%

Overview

📋 About: BDA is an Australian medicinal cannabis, Cannabidiol (CBD) and hemp healthcare company that delivers premium, proven and trusted products for both the consumer and medicinal markets. 

🌏  Macro Theme: The past six months has seen a large global regulatory shift with regards to cannabis classification. In Australia, the Therapeutic Goods Administration (TGA) announced a decision to down schedule CBD products to Schedule 3 (Pharmacist Only) medicines.

Additionally, a decision from the United Nations Commission on Narcotic Drugs accepted a recommendation from the World Health Organisation to remove cannabis and its derivatives from Schedule IV of the Single Convention on Narcotic Drugs.

The US House of Representatives also passed the Marijuana Opportunity Reinvestment and Expungement (“MORE”) Act to decriminalise cannabis at a national level. The bill aims to remove cannabis from the US controlled substance act, while recognising the therapeutic benefits of the drug.

Why We Invested

Icon
Relationship with Health and Happiness Group
Icon
International expansion currently underway
Icon
Regulations opening up across the globe
Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere